Dr. Danilov on ELEVATE-TN Trial Results in CLL

Video

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, associate professor of medicine, Program in Molecular and Cellular Biology, Cancer Biology Graduate Program, Oregon Health & Science University School of Medicine, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia (CLL).

The ELEVATE-TN trial randomized treatment-naïve patients with CLL to acalabrutinib (Calquence) in combination with obinutuzumab (Gazyva), single-agent acalabrutinib, or chlorambucil in combination with obinutuzumab, explains Danilov. Results showed a progression-free survival advantage in both acalabrutinib arms, marking the first study to demonstrate an advantage for the combination of acalabrutinib plus obinutuzumab versus acalabrutinib alone; however, the study was not powered to assess that difference, says Danilov.

Responses were up to 94% in patients who received acalabrutinib. Further, toxicities were low and less than 10% of patients discontinued acalabrutinib due to adverse events (AEs). Although atrial fibrillation is certainly a concern with BTK inhibitors, approximately around 3% of patients in this study experienced this AE on acalabrutinib, concludes Danilov.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD